How Firebrick Pharma’s Nasodine Surged in Sales Despite Rising Losses

• Nasodine revenue jumped to $293,422 from $14,522 in prior year
• Net loss widened 124% to $2.63 million due to lower R&D tax incentives and higher expenses
• Market entries expanded to US, Singapore, Fiji with new licensing agreement covering Singapore, Malaysia, Brunei, Mauritius
• Cash reserves rose to $983,350 supported by $1.89 million equity raises